文献速递糖尿病

抗高血糖药物:基于理赔数据估计启用二线药物前一线治疗的使用情况

Antihyperglycemic Medications: A Claims-Based Estimate of First-line Therapy Use Prior to Initialization of Second-line Medications.
PubMed 文献 · Diabetes Care · 2017-09-13

该回顾性横断面研究利用2010至2015年美国Aetna理赔数据,纳入52,544例2型糖尿病患者,评估启用二线治疗前60天内二甲双胍的推荐使用情况。在22,956例启用二线治疗的患者中,仅1,875例(8.2%)有推荐使用二甲双胍的证据,6,441例(28.0%)无既往二甲双胍理赔证据;敏感性分析最高估计仅49.5%可能达到推荐使用。作者结论认为二线治疗常在缺乏一线治疗推荐使用证据时启动,需在诊疗点和人群层面监测并改善指南依从性。

要点

  • 启用二线治疗的2型糖尿病患者中仅8.2%有前60天推荐使用二甲双胍的证据。
  • 28.0%的患者在启用二线治疗前无任何二甲双胍理赔证据。
  • 无推荐使用二甲双胍证据者更可能被加用其他二线药物或胰岛素(P < 0.001)。

核心结论

  • 尽管有已发表的指南,二线治疗常在缺乏一线治疗推荐使用证据的情况下启动。
  • 表面上的治疗失败可能实际上归因于不遵循指南,这种情况很常见。
  • 需要在诊疗点和人群层面建立流程以监测和改善指南依从性。

研究设计与样本

  • 回顾性横断面研究,使用2010至2015年美国健康福利公司Aetna承保个体的不可识别会员理赔数据。
  • 纳入有两次医生理赔或一次因2型糖尿病住院诊断的受益人,共52,544例2型糖尿病患者符合条件。
  • 通过敏感性分析改变对使用低成本仿制药处方药计划的受益人百分比的估计。

主要发现

  • 在22,956例接受二线治疗的患者中,仅1,875例(8.2%)有前60天内推荐使用二甲双胍的证据。
  • 6,441例(28.0%)在启用二线治疗前无既往服用二甲双胍的理赔证据。
  • 敏感性分析最高范围下,仅49.5%的患者可能达到推荐使用。
  • 若无推荐使用二甲双胍的证据即启用初始二线药物,患者更可能被加用其他二线抗高血糖药物或胰岛素(P < 0.001)。

关键数值与推荐

  • 美国糖尿病协会推荐二甲双胍作为2型糖尿病的一线治疗。
  • 推荐使用二甲双胍通过60天内的覆盖天数比例来衡量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The American Diabetes Association recommends metformin as first-line therapy for type 2 diabetes. However, nonadherence to antihyperglycemic medication is common, and a clinician could confuse nonadherence with pharmacologic failure, potentially leading to premature prescribing of second-line therapies. We measured metformin use prior to second-line therapy initialization. RESEARCH DESIGN AND METHODS: This retrospective cross-sectional study used unidentifiable member claims data from individuals covered from 2010 to 2015 by Aetna, a U.S. health benefits company. Beneficiaries with two physician claims or one hospitalization with a type 2 diabetes diagnosis were included. Recommended use of metformin was measured by the proportion of days covered over 60 days. Through sensitivity analysis, we varied estimates of the percentage of beneficiaries who used low-cost generic prescription medication programs. RESULTS: A total of 52,544 individuals with type 2 diabetes were eligible. Of 22,956 patients given second-line treatment, only 1,875 (8.2%) had evidence of recommended use of metformin in the prior 60 days, and 6,441 (28.0%) had no prior claims evidence of having taken metformin. At the top range of sensitivity, only 49.5% patients could have had recommended use. Patients were more likely to be given an additional second-line antihyperglycemic medication or insulin if they were given their initial second-line medication without evidence of recommended use of metformin (P < 0.001). CONCLUSIONS: Despite published guidelines, second-line therapy often is initiated without evidence of recommended use of first-line therapy. Apparent treatment failures, which may in fact be attributable to nonadherence to guidelines, are common. Point-of-care and population-level processes are needed to monitor and improve guideline adherence.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Tseng YJ, Steinberg G, Fox KP, et al. Antihyperglycemic Medications: A Claims-Based Estimate of First-line Therapy Use Prior to Initialization of Second-line Medications. Diabetes Care. 2017. PMID: 28903978. doi:10.2337/dc17-0213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。